vanoxerine has been researched along with Disease Models, Animal in 26 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted." | 1.43 | Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy. ( Gao, ZB; Gunosewoyo, H; Liu, T; Pang, T; Shi, JJ; Shi, M; Sun, H; Tang, J; Xu, YZ; Yang, F; Yu, LF; Zhang, W; Zheng, YM, 2016) |
| "Vanoxerine is a promising, new, investigational antiarrhythmic drug." | 1.37 | Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. ( Brown, AM; Cakulev, I; Khrestian, CM; Lacerda, AE; Ryu, K; Waldo, AL, 2011) |
| "Schizophrenia is associated with a cerebral glutathione deficit, which may leave the brain susceptible to oxidants." | 1.32 | Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. ( Castagné, V; Cuenod, M; Do, KQ; Rougemont, M, 2004) |
| " Drugs were subsequently tested for potential long-lasting effects on brain tissue 5-HT after repeated dosing (2." | 1.31 | Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity. ( Ayestas, MA; Baumann, MH; Dersch, CM; Partilla, JS; Rothman, RB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 13 (50.00) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, H | 1 |
| Shi, M | 1 |
| Zhang, W | 1 |
| Zheng, YM | 1 |
| Xu, YZ | 1 |
| Shi, JJ | 1 |
| Liu, T | 1 |
| Gunosewoyo, H | 1 |
| Pang, T | 1 |
| Gao, ZB | 1 |
| Yang, F | 1 |
| Tang, J | 1 |
| Yu, LF | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Górny, M | 1 |
| Wnuk, A | 1 |
| Kamińska, A | 1 |
| Kamińska, K | 1 |
| Chwatko, G | 1 |
| Bilska-Wilkosz, A | 1 |
| Iciek, M | 1 |
| Kajta, M | 1 |
| Rogóż, Z | 1 |
| Lorenc-Koci, E | 1 |
| Bastos, JR | 1 |
| Perico, KM | 1 |
| Marciano Vieira, ÉL | 1 |
| Teixeira, AL | 1 |
| Machado, FS | 1 |
| de Miranda, AS | 1 |
| Moreira, FA | 1 |
| Oliva, I | 1 |
| Fernández, M | 1 |
| Martín, ED | 1 |
| Novick, AM | 1 |
| Forster, GL | 1 |
| Hassell, JE | 1 |
| Davies, DR | 1 |
| Scholl, JL | 1 |
| Renner, KJ | 1 |
| Watt, MJ | 1 |
| Queiroz, AI | 1 |
| de Araújo, MM | 1 |
| da Silva Araújo, T | 1 |
| de Souza, GC | 1 |
| Cavalcante, LM | 1 |
| de Jesus Souza Machado, M | 1 |
| de Lucena, DF | 1 |
| Quevedo, J | 1 |
| Macêdo, D | 1 |
| van Enkhuizen, J | 2 |
| Milienne-Petiot, M | 1 |
| Geyer, MA | 3 |
| Young, JW | 3 |
| Fujiwara, T | 1 |
| Sanada, M | 1 |
| Kofuji, T | 1 |
| Akagawa, K | 1 |
| Hewitt, KN | 2 |
| Marsden, CA | 2 |
| Hollis, CP | 2 |
| Fone, KC | 2 |
| Goey, AK | 1 |
| Minassian, A | 1 |
| Perry, W | 1 |
| Paulus, MP | 1 |
| Cakulev, I | 1 |
| Lacerda, AE | 1 |
| Khrestian, CM | 1 |
| Ryu, K | 1 |
| Brown, AM | 1 |
| Waldo, AL | 1 |
| Kooistra, K | 1 |
| Hiraide, S | 1 |
| Ueno, K | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, M | 1 |
| Yanagawa, Y | 1 |
| Yoshioka, M | 1 |
| Togashi, H | 1 |
| Nakai, M | 1 |
| Mori, A | 1 |
| Watanabe, A | 1 |
| Mitsumoto, Y | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 1 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Castagné, V | 2 |
| Cuénod, M | 2 |
| Do, KQ | 2 |
| Rougemont, M | 1 |
| Shah, YB | 1 |
| Prior, MJ | 1 |
| Morris, PG | 1 |
| Sotnikova, TD | 1 |
| Beaulieu, JM | 1 |
| Barak, LS | 1 |
| Wetsel, WC | 1 |
| Caron, MG | 1 |
| Gainetdinov, RR | 1 |
| Kamdar, NK | 1 |
| Miller, SA | 1 |
| Syed, YM | 1 |
| Bhayana, R | 1 |
| Gupta, T | 1 |
| Rhodes, JS | 1 |
| Rothman, RB | 2 |
| Baumann, MH | 2 |
| Prisinzano, TE | 1 |
| Newman, AH | 1 |
| Carlsson, ML | 1 |
| Ayestas, MA | 1 |
| Dersch, CM | 1 |
| Partilla, JS | 1 |
| Stafford, D | 1 |
| Rice, KC | 1 |
| Lewis, DB | 1 |
| Glowa, JR | 1 |
1 review available for vanoxerine and Disease Models, Animal
| Article | Year |
|---|---|
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.
Topics: Animals; Behavior, Animal; Benztropine; Cocaine-Related Disorders; Conditioning, Psychological; Dise | 2008 |
25 other studies available for vanoxerine and Disease Models, Animal
| Article | Year |
|---|---|
Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Injecti | 2016 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Glutathione Deficiency and Alterations in the Sulfur Amino Acid Homeostasis during Early Postnatal Development as Potential Triggering Factors for Schizophrenia-Like Behavior in Adult Rats.
Topics: Amino Acids, Sulfur; Animals; Buthionine Sulfoximine; Disease Models, Animal; DNA Methylation; Gluta | 2019 |
Inhibition of the dopamine transporter as an animal model of bipolar disorder mania: Locomotor response, neuroimmunological profile and pharmacological modulation.
Topics: Animals; Antidepressive Agents; Aripiprazole; Bipolar Disorder; Brain; Cytokines; Disease Models, An | 2018 |
Dopamine release regulation by astrocytes during cerebral ischemia.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Aspartic Acid; Astrocytes; Calcium; Corpus Striatum; | 2013 |
Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stress.
Topics: Adrenergic Uptake Inhibitors; Animals; Desipramine; Disease Models, Animal; Dominance-Subordination; | 2015 |
GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs.
Topics: Affect; Animals; Antimanic Agents; Bipolar Disorder; Brain; Disease Models, Animal; Dopamine Uptake | 2015 |
Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features.
Topics: Acetylcholine; Animals; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Cholinesterase Inhibit | 2015 |
Unusual social behavior in HPC-1/syntaxin1A knockout mice is caused by disruption of the oxytocinergic neural system.
Topics: Amygdala; Analysis of Variance; Animals; Benzoxazines; Disease Models, Animal; Dopamine; Dopamine Up | 2016 |
Behavioural characterisation of the effects of acute and repeated administration of GBR 12909 in rats: further evaluation of a potential model of ADHD.
Topics: Acoustic Stimulation; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Dise | 2009 |
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior.
Topics: Animals; Behavior, Animal; Bipolar Disorder; Dextroamphetamine; Disease Models, Animal; Dopamine Pla | 2010 |
Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac | 2011 |
Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice.
Topics: Analysis of Variance; Animals; Antimanic Agents; Bipolar Disorder; Disease Models, Animal; Dopamine | 2013 |
Behavioural effects of monoamine reuptake inhibitors on symptomatic domains in an animal model of attention-deficit/hyperactivity disorder.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Biogenic Monoamines; Desip | 2013 |
1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Carbocyanines; Coloring Agents; Corpus Striatu | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development.
Topics: Aging; Animals; Animals, Newborn; Behavior, Animal; Body Weight; Brain Chemistry; Buthionine Sulfoxi | 2004 |
Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia.
Topics: Animals; Ascorbic Acid Deficiency; Body Weight; Brain; Brain Chemistry; Buthionine Sulfoximine; Cogn | 2004 |
Behavioural and pharmacological magnetic resonance imaging assessment of the effects of methylphenidate in a potential new rat model of attention deficit hyperactivity disorder.
Topics: Analysis of Variance; Animals; Animals, Newborn; Attention Deficit and Disruptive Behavior Disorders | 2005 |
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Di | 2005 |
Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice.
Topics: Alcohol Drinking; Alcoholic Intoxication; Animals; Behavior, Animal; Central Nervous System Depressa | 2007 |
The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.
Topics: Animals; Biogenic Monoamines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Uptake Inhibitor | 1995 |
Serotonin transporters, serotonin release, and the mechanism of fenfluramine neurotoxicity.
Topics: Analysis of Variance; Animals; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease | 2000 |
Response requirements and unit dose modify the effects of GBR 12909 on cocaine-maintained behavior.
Topics: Animals; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Disease Models, Anim | 2000 |